AtaiBeckley Inc. (ATAI)Healthcare | Biotechnology | New York, United States |
USD
|
Hot Take ↕ | Oct. 10, 2026, 8:51 a.m. UTC
The immediate outlook is overwhelmingly bullish due to the reported acquisition talks with Eli Lilly, which sent shares soaring 65% after hours and established a clear near-term catalyst. With the stock trading near its 52-week high and analysts projecting significant upside based on this potential deal, the momentum is undeniable for a short-term entry. However, the long-term investment case remains neutral because the company lacks a multi-year price history to assess its historical business quality trajectory, and the fundamentals currently show severe distress with negative earnings, massive losses, and no dividend capability. The valuation metrics are distorted by the pending M&A event rather than organic growth, making a long-term hold speculative until the deal closes or fails. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.429 |
| Revenue per Share | 0.014 |
| Market Cap | 2,725,855,232 |
| Forward P/E | -15.31 |
| Beta | 1.55 |
| Website | https://www.ataibeckley.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5061475 |
| Address1 | 250 West 34th Street |
| All Time High | 22.91 |
| All Time Low | 1.025 |
| Ask | 7.2 |
| Ask Size | 200 |
| Average Daily Volume10 Day | 19,615,180 |
| Average Volume | 15,022,175 |
| Average Volume10Days | 19,615,180 |
| Beta | 1.552 |
| Bid | 7.17 |
| Bid Size | 5,900 |
| Book Value | 0.478 |
| City | New York |
| Country | United States |
| Currency | USD |
| Current Price | 7.35 |
| Current Ratio | 8.578 |
| Date Short Interest | 1,788,134,400 |
| Day High | 7.365 |
| Day Low | 7.3 |
| Debt To Equity | 2.429 |
| Ebitda | -140,791,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -17.788 |
| Enterprise To Revenue | 560.019 |
| Enterprise Value | 2,504,403,200 |
| Exchange | NGM |
| Exchange Timezone Name | UTC |
| Fifty Day Average | 6.8981 |
| Fifty Two Week High | 7.45 |
| Fifty Two Week Low | 3.265 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,784,295,000 |
| Float Shares | 308,411,059 |
| Forward Eps | -0.47996 |
| Forward P E | -15.313776 |
| Free Cashflow | -74,669,752 |
| Full Time Employees | 99 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 7.35 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -70,624,000 |
| Held Percent Insiders | 0.02183 |
| Held Percent Institutions | 0.523 |
| Implied Shares Outstanding | 370,864,669 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments. The company develops rapid-acting and durable therapies for conditions with limited treatment options. Its pipeline includes BPL-003 (mebufotenin benzoate), an intranasal formulation in Phase 2 and 3 clinical studies for treatment-resistant depression and alcohol use disorder; ELE-101, a serotonergic psychedelic for major depressive disorder; and RL-007, an orally bioavailable pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia. The company's pipeline also comprises VLS-01, an oral transmucosal film formulation of N, N-Dimethyltryptamine in Phase 2 clinical study for treatment-resistant depression; EMP-01, an oral formulation of the R-enantiomer of 3,4-methylenedioxy-methamphetamine in Phase 2 clinical study for social anxiety disorder; and EGX-A and EGX-B, non-hallucinogenic 5-HT2A receptor agonists for treatment-resistant depression. Additionally, it offers COMP360, a psilocybin therapy; and GRX-917, a treatment for anxiety, depression, and various neurological disorders. The company has additional operations in Germany and Canada. AtaiBeckley Inc. was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York. AtaiBeckley Inc. operates as a subsidiary of Eli Lilly and Company. |
| Long Name | AtaiBeckley Inc. |
| Market Cap | 2,725,855,232 |
| Max Age | 86,400 |
| Message Board Id | finmb_710359021 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -668,193,024 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,725,855,317 |
| Number Of Analyst Opinions | 6 |
| Open | 0.0 |
| Operating Cashflow | -127,103,000 |
| Operating Margins | -25.90434 |
| Payout Ratio | 0.0 |
| Phone | 332 282 0507 |
| Previous Close | 7.35 |
| Price Hint | 2 |
| Price To Book | 15.37657 |
| Price To Sales Trailing12 Months | 609.53827 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.285 |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 2.84615 |
| Regular Market Day High | 7.365 |
| Regular Market Day Low | 7.3 |
| Regular Market Open | 0.0 |
| Regular Market Previous Close | 7.35 |
| Regular Market Volume | 0 |
| Return On Assets | -0.39026 |
| Return On Equity | -4.17207 |
| Revenue Growth | 1.37 |
| Revenue Per Share | 0.014 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 370,864,669 |
| Shares Percent Shares Out | 0.051799998 |
| Shares Short | 19,201,689 |
| Shares Short Previous Month Date | 1,785,456,000 |
| Shares Short Prior Month | 19,857,150 |
| Short Name | AtaiBeckley Inc. |
| Short Percent Of Float | 0.061100002 |
| Short Ratio | 2.84 |
| State | NY |
| Symbol | ATAI |
| Target High Price | 9.25 |
| Target Low Price | 7.45 |
| Target Mean Price | 8.11667 |
| Target Median Price | 7.75 |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 225,808,000 |
| Total Cash Per Share | 0.609 |
| Total Debt | 4,285,000 |
| Total Revenue | 4,472,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.79 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 4.736475 |
| Underlying Symbol | ATAI |
| Uuid | 8,699f3bf-7398-34d0-b0ba-129948e2583d |
| Volume | 0 |
| Website | https://www.ataibeckley.com |
| Zip | 10,119 |